FOR IMMEDIATE RELEASE

Contact: Joanne Forster
CureDuchenne
joanne@cureduchenne.org
310.498.7585

Catabasis Pharmaceuticals and CureDuchenne to Host Webinar on Edasalonexent in Development for the Treatment of Duchenne

NEWPORT BEACH, Calif. (March 14, 2019) – Catabasis Pharmaceuticals, Inc. and nonprofit CureDuchenne announced today they have partnered to host a free webinar to provide Duchenne muscular dystrophy patients, caregivers and advocates an update on three edasalonexent clinical trials. The hour-long webinar will take place on Thursday, March 28, 2019, at 10am PDT/1pm EDT. Participants must register in advance at**:** https://bit.ly/2H7glvx.

The webinar will provide an update on the currently enrolling global Phase 3 PolarisDMD trial and introduce the new open-label extension GalaxyDMD trial. Additionally, results from the Phase 2 MoveDMD trial will be discussed.

Webinar participants will be:

- Dr. Erika Finanger, M.D., Associate Professor of Pediatrics, Division of Neurology, School of Medicine at Oregon Health & Science University and Principal Investigator for the MoveDMD, PolarisDMD and GalaxyDMD trials
- Dr. Joanne Donovan, M.D., Ph.D., Chief Medical Officer at Catabasis Pharmaceuticals
- Maria Mancini, Vice President of Clinical Operations at Catabasis Pharmaceuticals

"We applaud CureDuchenne's commitment to improving and extending the lives of those affected by Duchenne and are pleased to join them to educate families about our ongoing trials with edasalonexent as we work towards a new potential treatment option," said Dr. Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis.

For anyone unable to tune in to the live webinar, they can listen and watch the archived presentation on the CureDuchenne website immediately following the live production.

About Catabasis Pharmaceuticals
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.

About CureDuchenne

CureDuchenne is the nation's leading nonprofit organization dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 patients worldwide, most of them boys and young men. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org, and follow us on Facebook, Twitter and YouTube.

# # #